| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:24615531 | IVR | 550 mg/L | 550 mg/L | Decreased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations |
| IVR | 550 mg/L | 550 mg/L | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 550 mg/L | 550 mg/L | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 550 mg/L | 550 mg/L | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 550 mg/L | 550 mg/L | Increased bilurubin content | Metabolic endocrine-mediated perturbations | |
| IVR | 550 mg/L | 550 mg/L | Decreased Aspartate aminotransferase (AST) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 550 mg/L | 550 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 550 mg/L | 550 mg/L | Affects gluconeogenesis | Metabolic endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.